Le Lézard
Classified in: Health
Subjects: TDS, FVT

Lucid Diagnostics to Participate in Upcoming Investor Conferences


NEW YORK, Aug. 5, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that management will participate in the following upcoming investor conferences:

The live and archived webcast of the Canaccord Genuity fireside chat can be accessed by clicking here or by visiting the Investor Relations Section of the Lucid Diagnostics website.  A replay of the webcast will be available on the website for 30 days following the conclusion of the live broadcast.

About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

SOURCE Lucid Diagnostics


These press releases may also interest you

at 09:00
BioSyent Announces Agreement to Purchase Tibelia® (tibolone) Assets
BioSyent Inc. ("BioSyent", "the Company", TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc., has entered into an agreement to acquire certain assets enabling it to supply Tibelia®, a tibolone-based hormone...

at 09:00
Ipsen's Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade
European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver diseaseApproval follows positive CHMP opinion based on ELATIVE phase III trial...

at 09:00
ER Doctor Urges Parents to Vaccinate Their Children as Flu Deaths Spike
Houston emergency room physician, Dr. Christopher Langan, is urging parents to give their children flu shots between now and end of October to minimize the chances of severe illnesses and complications should they become infected. "Any number of...

at 09:00
Renowned Herndon, VA, Plastic Surgeon, Dr. Amir Ghaznavi, Receives the 2024 Top Patient Rated Doctor Award from Find Local Doctors
At AMG Plastic Surgery, located at 13454 Sunrise Valley Dr., Ste 130 in Herndon, VA, Dr. Amir Ghaznavi, and his team specialize in a wide range of breast and body procedures, serving the Northern Virginia community, including Reston, Fairfax and...

at 09:00
DISCOVER FH Collaboration With Family Heart Foundation, UT Southwestern, and Partners
GENinCode Plc (AIM:GENI), the genetics company focused on the prevention of cardiovascular disease and ovarian cancer, announces its collaboration with The Family Heart Foundation®, UT Southwestern, and other partner members to use the LIPID...

at 08:58
Strengthening North America's Defense Against African Swine Fever
Statement from Canada's Chief Veterinary Officer, Dr. Mary Jane Ireland, on the North American African Swine Fever (ASF) Forum "Canada was proud to host the 4th North American African Swine Fever (ASF) Forum, which brought together international and...

More news about Health...


News published on and distributed by: